Evidence map›Paper›PMID 35469698›Full record

ArticleVaccine2022

Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder.

Fatima A Hamid, Cheryl L Marker, Michael D Raleigh, Aaron Khaimraj, Scott Winston, Paul R Pentel, Marco Pravetoni

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Fatima A HamidDepartment of Pharmacology, University of Minnesota Medical School, 321 Church Street, SE (Room 6-120 Jackson Hall), Minneapolis, MN 55455, United States.
Cheryl L MarkerDepartment of Pharmacology, University of Minnesota Medical School, 321 Church Street, SE (Room 6-120 Jackson Hall), Minneapolis, MN 55455, United States. Electronic address: marke027@umn.edu.
Michael D RaleighDepartment of Pharmacology, University of Minnesota Medical School, 321 Church Street, SE (Room 6-120 Jackson Hall), Minneapolis, MN 55455, United States; Hennepin Healthcare Research Institute, 901 South 6th Street #S3.340, Minneapolis, MN 55415, United States.
Aaron KhaimrajDepartment of Pharmacology, University of Minnesota Medical School, 321 Church Street, SE (Room 6-120 Jackson Hall), Minneapolis, MN 55455, United States.
Scott WinstonWinston Biopharmaceutical Consulting, 4475 Laguna Place #215, Boulder, CO 80303, United States.
Paul R PentelHennepin Healthcare Research Institute, 901 South 6th Street #S3.340, Minneapolis, MN 55415, United States.
Marco PravetoniDepartment of Pharmacology, University of Minnesota Medical School, 321 Church Street, SE (Room 6-120 Jackson Hall), Minneapolis, MN 55455, United States; Department of Psychiatry & Behavioral Sciences, University of Washington School of Medicine, Center for Medication Development for Substance Use Disorders, 325 Ninth Avenue, Box 359911, Seattle, WA 98104, United States.
University of Minnesota · USHennepin Healthcare Research Institute · USUniversity of Washington · US

Funding

Phase 1a/1b Clinical Trials of Multivalent Opioid Vaccine ComponentsUG3DA047711 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI COMER, SANDRA D, PRAVETONI, MARCO · 2018 to 2019
$9.4M
Vaccines for prescription opioid and heroin abuseU01DA038876 · NIDA · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · PI PENTEL, PAUL R, PRAVETONI, MARCO · 2015 to 2018
$7.4M
NIDA NIH HHS U01 DA038876NIDA NIH HHS UG3 DA047711
6 · The paper itself

Abstract

Opioid use disorders (OUD) and overdose represent a public health threat, resulting in thousands of deaths annually worldwide. Vaccines offer a promising treatment for OUD and potentially the prevention of fatal overdoses. The Oxy(Gly)

Indexed as

Drug OverdoseOpioid-Related DisordersAluminumAnimalsOxycodoneRatsRats, Sprague-DawleyVaccines, ConjugateAluminumOxycodoneVaccines, ConjugateFDAGLPINDOpioidOpioid use disorderOxycodoneSafetyToxicityVaccine

Identifiers

PMID35469698
PMCPMC9186020
OpenAlexW4224273325

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.